Community/Retail

From newsworthy moments to groundbreaking research, these are the most popular articles published on Pharmacy Times® during 2019.

Officials with the FDA have approved Eisai’s lemborexant (Dayvigo) 5 mg and 10 mg for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

The applications for the first generics of apixaban (Eliquis, Bristol-Meyers Squibb) tablets were approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation

Ubrogepant is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved by the agency for the acute treatment of migraine.